Retatrutide: the triple-hormone obesity drug in trials

Retatrutide is an experimental weight-loss drug still in clinical trials. It is NOT approved by the FDA or sold in India, so do not seek or buy it.

13 Jul 2026 · Burnie Academy
retatrutide clinical-trials glp-1 weight-loss-medicines

You may have heard buzz about a new weight-loss shot called retatrutide. Friends say it melts fat fast. But here is the truth: retatrutide is still being tested. It is not a real medicine you can buy yet. Let us look at what it really is, in simple words.

What is retatrutide?

Retatrutide (also called LY3437943) is made by Eli Lilly. It is called a "triple agonist." That means it copies THREE body hormones at once. Most obesity shots copy one or two. This one copies three: GLP-1, GIP, and glucagon. It is given as a small weekly shot under the skin. But please note: it is investigational. That means it is still in tests and NOT approved by the FDA. No doctor can prescribe it. No pharmacy sells it in India.

Sources: Eli Lilly and Company. Press release: 'Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.' May 21, 2026.

The three hormones it copies

GLP-1 receptor

Lowers appetite and makes you feel full. This is the same target used by semaglutide (Wegovy).

GIP receptor

Helps the body handle sugar better. Works with GLP-1 for extra weight loss, like in tirzepatide (Mounjaro).

Glucagon receptor

The new third piece. Scientists think it may boost fat-burning and energy use, on top of the fullness effect.

Sources: Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.

Retatrutide is approved and you can buy it online in India now.

mostly false

Mostly false. Eli Lilly itself says retatrutide is an investigational molecule that is legally available only to participants in Lilly's clinical trials. It is not approved by the FDA, not sold by any pharmacy, and not legal to buy in India. Any website offering "retatrutide for sale" is selling fakes or scams. Do not order it.

Sources: Eli Lilly and Company. Press release, May 21, 2026.

What the trials found so far

In the phase-2 test, 338 adults with obesity took retatrutide or a placebo (a dummy shot) for 48 weeks. The best group got the 12 mg dose. They lost about 24.2% of their body weight by week 48. That is roughly one-quarter of their weight gone. People on the dummy shot lost only 2.1%. This was a strong, promising result. Now bigger phase-3 tests are running. Lilly calls this the TRIUMPH program. One of these, TRIUMPH-1, is a Phase 3, 80-week trial in adults with obesity. Results so far look good, but the drug is still not approved.

Sources: Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. · Eli Lilly and Company. Press release, May 21, 2026 (TRIUMPH-1 results).

What to do while you wait

The bottom line

Retatrutide is exciting because it targets three hormones at once and may burn extra fat. Early trials show big weight loss. But it is still experimental, not approved, and years away from any pharmacy. Do not seek or buy it. If you want medicine help today, talk to your doctor about options that are already approved.